A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

August 12, 2025

Study Completion Date

August 12, 2025

Conditions

Healthy

Interventions

DRUG

MK-7602

Capsule

DRUG

Efavirenz

Tablet

Trial Locations (1)

Fortrea Clinical Research Unit Inc ( Site 0001), Daytona Beach

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06797674 - A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) | Biotech Hunter | Biotech Hunter